International Biotechnology Trust (IBT)
Category Sector Equity Biotechnology
This investment trust can be held in an Investment ISA, SIPP and Investment Account
Some Investment Trusts include direct costs as part of their Ongoing charge, such as the annual management charge. For those that show Ongoing charges as 0% or a dash please review the investment literature for details on the charges that will apply. The Financial Conduct Authority will review this in 2025.
If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice.
If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice.
Sell
546.00p
Buy
560.00p
6.5862p (+1.20%)
Discount/Premium
-12.42%
Estimated NAV
628.011p
Prices updated at 16 May 2025, 08:18 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Investment objective
The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with suitably experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide
, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Price
- Performance
- Charges & documents
- Shares & trades
- Dividends
- Portfolio
- News & dates
- Trust info
- Director info
Company name
Schroder Unit Trusts Limited
Legal structure
Closed Ended Investment Company
Domicile
United Kingdom
Fiscal year end
31 Aug 2025
Launch date
06 May 1994
Fund manager
Ailsa Craig
Manager start date
01 Mar 2021
Fund manager biography
Managed IBT since 2006 and took over as co-lead manager in March 2021. Before moving to Schroders with IBT, Ailsa was managing the trust at SV Health Investors. She started her career at Insight Investment / Rothschild Asset Management (merged 2003) within the Global/US investment team and then worked at Baring Asset Management for two years as a research analyst, covering pharmaceutical and biotechnology stocks. Ailsa has a BSc (Hons) in Biology from the University of Manchester. She was awarded the IMC in 2002 and the Securities Institute Diploma in 2007.
Head office
1 London Wall Place
London
United Kingdom
EC2Y 5AU
